Skip to main content

Lawsuit Against Makers of Ozempic, Mounjaro Claim Meds Caused 'Stomach Paralysis'

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

THURSDAY, Aug. 3, 2023 -- A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk of severe stomach problems.

The lawsuit seeks “very significant” but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Fla.-based firm Morgan & Morgan.

Pennock filed the lawsuit Wednesday on behalf of Jaclyn Bjorklund, 44, NBC News reported.

The lawsuit against Novo Nordisk and Eli Lilly claims Bjorklund was “severely injured” after taking the two diabetes drugs, which are part of a new class of medication called GLP-1 agonists.

Pennock said she is suffering "persistent" vomiting and severe gastroparesis, also known as stomach paralysis.

Gastroparesis slows or stops food from moving out of the stomach and into the small intestines. It can be caused by underlying medical issues, including diabetes, according to the American College of Gastroenterology. Infections and some medication can also cause it.

The GLP-1 agonists slow food’s movement and have been found to cause some GI issues in clinical trials. Those are listed as side effects on the drug labels.

Both Ozempic and Mounjaro have the phrase “delays gastric emptying” on their prescribing information, though they don’t specifically use the word “gastroparesis,” NBC News reported.

A U.S. Food and Drug Administration spokeswoman said it was unclear whether the GLP-1 medications contribute to gastroparesis.

"If newly identified safety signals are identified, the FDA will determine what actions are appropriate after a thorough review of the body of evidence," spokeswoman Chanapa Tantibanchachai said in a statement.

Eli Lilly did not respond to an NBC News request for comment, and a Novo Nordisk spokeswoman said the company was unaware of the lawsuit.

“Patient safety is of utmost importance to Novo Nordisk,” said spokeswoman Natalia Salomao. “We recommend patients take these medications for their approved indications and under the supervision of a health care professional.”

Sources

  • NBC News

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

It's Safe to Take GLP-1 Weight Loss Meds Before Surgery: Study

THURSDAY, June 6, 2024 -- Despite recent concerns that taking Ozempic, Wegovy or other GLP-1 medications might be unsafe before a surgery, a new review has uncovered no such...

Wegovy, Ozempic May Help Curb Alcohol Dependence

TUESDAY, June 4, 2024 -- Could the blockbuster GLP-1 meds like Wegovy and Ozempic have a role to play in helping people cut down on problem drinking? A new study suggests...

Could New Weight-Loss Drugs Be Changing Women's Taste for Sweets?

MONDAY, June 3, 2024 -- Ozempic and Wegovy appear to improve people’s sensitivity to tastes, potentially lowering their desire for sweets, a new study suggests. The active...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.